For how we live.
PREMIUM tested prasugrel alone against aspirin plus prasugrel in 2,216 STEMI patients in Japan. Monotherapy failed to show noninferiority, and the confidence interval sat above one.
LIBREXIA-ACS enrolled 14,194 patients before stopping for futility. Milvexian did not reduce events, but intracranial and fatal bleeding were identical to placebo, which is the class's whole premise.
Observational studies had linked proton pump inhibitors to fractures, dementia, kidney disease and more. A randomised trial collected all of those outcomes and found only enteric infections.
After 12 months, HbA1c was 6.5% among people managed by community health workers versus 7.1% among those referred to clinics. With 103 participants analysed, the confidence interval crosses zero.
The 162 mg group had 14.1% preterm or severe preeclampsia against 17.1% on 81 mg — a difference the trial could not distinguish from chance. Eight placental abruptions occurred on the higher dose and none on the lower.
A 13-year-old observational hypothesis finally got its randomised test. In ALASCCA, 160 mg of daily aspirin cut three-year recurrence from 14.1% to 7.7% in biomarker-selected patients.